MX2023008883A - Polimorfo de diclorhidrato de latrepirdina. - Google Patents

Polimorfo de diclorhidrato de latrepirdina.

Info

Publication number
MX2023008883A
MX2023008883A MX2023008883A MX2023008883A MX2023008883A MX 2023008883 A MX2023008883 A MX 2023008883A MX 2023008883 A MX2023008883 A MX 2023008883A MX 2023008883 A MX2023008883 A MX 2023008883A MX 2023008883 A MX2023008883 A MX 2023008883A
Authority
MX
Mexico
Prior art keywords
latrepirdine
dihydrochloride
polymorph
dmb
crystalline
Prior art date
Application number
MX2023008883A
Other languages
English (en)
Inventor
Boris Gorine
Marina Yurovskaya
Original Assignee
Bigespas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bigespas Ltd filed Critical Bigespas Ltd
Publication of MX2023008883A publication Critical patent/MX2023008883A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripción se refiere a un diclorhidrato de latrepirdina cristalino, forma DMB-I, su método de preparación, composición farmacéutica que lo contiene y sus usos. (ver Fórmula).
MX2023008883A 2021-02-01 2022-01-31 Polimorfo de diclorhidrato de latrepirdina. MX2023008883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/164,583 US12084440B2 (en) 2021-02-01 2021-02-01 Polymorph of latrepirdine dihydrochloride
PCT/CA2022/050136 WO2022160066A1 (en) 2021-02-01 2022-01-31 Polymorph of latrepirdine dihydrochloride

Publications (1)

Publication Number Publication Date
MX2023008883A true MX2023008883A (es) 2023-08-09

Family

ID=82612227

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008883A MX2023008883A (es) 2021-02-01 2022-01-31 Polimorfo de diclorhidrato de latrepirdina.

Country Status (9)

Country Link
US (2) US12084440B2 (es)
EP (1) EP4284800A1 (es)
JP (1) JP2024508375A (es)
KR (1) KR20230141807A (es)
AU (1) AU2022215018A1 (es)
CA (1) CA3207061A1 (es)
IL (1) IL304836A (es)
MX (1) MX2023008883A (es)
WO (1) WO2022160066A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
RU2338537C2 (ru) 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2009111540A1 (en) * 2008-03-04 2009-09-11 Medivation Neurology, Inc. Methods for preparing pyridylethyl-substituted carbolines
WO2011039670A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)

Also Published As

Publication number Publication date
US20220242860A1 (en) 2022-08-04
EP4284800A1 (en) 2023-12-06
KR20230141807A (ko) 2023-10-10
JP2024508375A (ja) 2024-02-27
WO2022160066A1 (en) 2022-08-04
IL304836A (en) 2023-09-01
US20240124441A1 (en) 2024-04-18
AU2022215018A1 (en) 2023-09-14
US12084440B2 (en) 2024-09-10
CA3207061A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20125579B (en) Novel crystalline form vi of agomelatine, preparation method thereof and pharmaceutical compositions containing same
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
TN2018000239A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
GEP20094577B (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
WO2020141419A3 (en) Novel salts and polymorphic form of bempedoic acid
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
EP4327880A3 (en) Solid state form of ribociclib succinate
ZA202207729B (en) Solid state form of pyroxasulfone
MY194364A (en) Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof
MX2020005564A (es) Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
WO2018193090A3 (en) METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF
WO2020127208A8 (en) Pharmaceutical process and intermediates
CR20200211A (es) Derivados de piridinona y uso como inhibidores selectivos de alk-2
MX2023008883A (es) Polimorfo de diclorhidrato de latrepirdina.
WO2022040111A3 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
MX2019015478A (es) Una nanosuspension farmaceutica para el tratamiento de infeccion por vih.